Dr Jeff Domsic, Product Manager Charles River Laboratories, discusses ATP-bioluminescence testing aligned with new regulatory guidelines. Over the past decade, the emergence of advanced therapy medicinal products (ATMPs) has fundamentally changed the approach to developing, manufacturing, administering, and treating diseases. These advanced modalities show significant promise and introduce various safety testing challenges. Industry and regulatory […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!